Formulary Search
Search Results : Diabetes Mellitus (Insulin Lispro - Humalog - Diabetes Mellitus)
Records returned : 66 (on 16 Jul 2025 at 23:08:33).
Return to search results for ' Diabetes Mellitus '.
Show Icon and Status Keys
Drug
Indication
Status
Restrictions/Comments
Formulary Status
Links
Indication :
Status :
Formulations :
- Cartridges
- Pre-filled pen
- Vials
Restrictions / Comments:
Important
Prescribe by brand and state form. Admelog (biosimilar insulin lispro) is lower cost and should be considered in preference to Humalog.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Important
Inadequately controlled diabetes mellitus
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Important
Existing patients would not be expected to change therapy unless appropriate to do so.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Important
Sitagliptin is the preferred DPP4.
Reserve combination products for patients in whom separate components are less appropriate.
Existing patients would not be expected to change therapy unless appropriate to do so.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Cartridges
- Pre-filled pen
Restrictions / Comments:
Important
Prescribe by brand and state form.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Cartridges
- Pre-filled pen
- Vials
Restrictions / Comments:
Important
Prescribe by brand and state form.
Formulary Status :
Links :
7. Biphasic Lispro Insulin - Humalog Mix 25
Drug:
Biphasic Lispro Insulin - Humalog Mix 25
(Insulin)
Indication :
Status :
Formulations :
- Cartridges
- Pre-filled pen
- Vials
Restrictions / Comments:
Important
Prescribe by brand and state form.
Formulary Status :
Links :
8. Biphasic Lispro Insulin - Humalog Mix 50
Drug:
Biphasic Lispro Insulin - Humalog Mix 50
(Insulin)
Indication :
Status :
Formulations :
- Not Specified
Restrictions / Comments:
Important
Prescribe by brand and state form.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Important
Empagliflozin is the preferred SGLT-2 Canagliflozin is not a preferred treatment option. Canagliflozin (Invokana?, Vokanamet?): signal of increased risk of lower extremity amputations observed in trial in high cardiovascular risk patients - GOV.UK.
Trusts restrict to diabetic team initiation only.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Important
Empagliflozin is the preferred SGLT2.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Important
Type 2 diabetes.
Empagliflozin is the preferred SGLT-2
Dapagliflozin is not a preferred treatment option.
Trusts restrict to diabetic team initiation only.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Important
Not licensed in Type 1 diabetes. Not to be initiated in new Type 1 patients.
Shared care remains in place for existing patients only.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Important
Empagliflozin is the preferred SGLT2.
Reserve combination products for patients in whom separate components are less appropriate.
Links :
Indication :
Status :
Formulations :
- Subcutaneous injection (sc)
Restrictions / Comments:
Important
Preferred
Preferred GLP-1 for WEEKLY injection.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Preferred
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Important
Reserve combination products for patients in whom separate components are less appropriate.
Existing patients would not be expected to change therapy unless appropriate to do so.
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Important
Empagliflozin is the preferred SGLT-2.
Ertugliflozin is a treatment option.
Trusts restrict to diabetic team initiation only.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Not Specified
Restrictions / Comments:
Important
Exenatide is not a preferred treatment option. The preferred GLP-1 for WEEKLY injection is dulaglutide.
Prescribing may continue on existing patients.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Important
SASH restricted to specialist monogenic clinic for use in specific diabetic subtypes (unlicensed drug - hospital only prescribing)
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Preferred
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Modified release
Restrictions / Comments:
Important
Immediate release tablets are preferred
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Important
Not a preferred treatment option.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Cartridges
- Pre-filled pen
- Vials
Restrictions / Comments:
Important
For adult patients ONLY
Prescribe by brand and state form.
Initiation by diabetologists only. A minimum prescribing duration of three months by secondary care before transferring to primary care.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Cartridges
- Pre-filled pen
- PumpCart
- Vials
Restrictions / Comments:
Important
Biosimilar insulin aspart (Trurapi) should be used in preference to NovoRapid. Prescribe by brand and state form.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Cartridges
- Pre-filled pen
- Vials
Restrictions / Comments:
Important
Preferred
Prescribe by brand and state form. Lower-cost biosimilar. Preferred for new patients.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Cartridges
- Pre-filled pen
Restrictions / Comments:
Important
Initiation by Diabetes team only. Prescribe by brand.
Insulin degludec is available in strengths of 100units/mL and 200units/mL - ensure correct strength is prescribed and dispensed
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Cartridges
- Pre-filled pen
Restrictions / Comments:
Important
Levemir (insulin detemir Penfill / FlexPen) is being discontinued. Supplies are expected to run out by Dec 2026. It is recommended that this is not initiated in new patients.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Cartridges
- Pre-filled pen
Restrictions / Comments:
Important
Prescribe by brand and state form. Semglee (biosimilar) is a lower cost option for patients using a pre-filled pen.
Links :
Indication :
Status :
Formulations :
- Cartridges
- Pre-filled pen
- Vials
Restrictions / Comments:
Important
Prescribe by brand and state form. Semglee (biosimilar) is a lower cost option for patients using a pre-filled pen. Lantus remains an option in existing patients and those preferring a reusable pen.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Pre-filled pen
Restrictions / Comments:
Important
Preferred
Semglee (biosimilar insulin glargine) is the preferred brand for all new patients who require a pre-filled pen.
Prescribe by brand.
Note - Semglee is NOT available as cartridges for use in re-usable insulin pens.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Pre-filled pen
Restrictions / Comments:
Important
Initiation by diabetes consultants or GPs with a specialist interest in diabetes. For use in poorly controlled patients.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Cartridges
- Pre-filled pen
- Vials
Restrictions / Comments:
Important
Prescribe by brand and state form.
SASH - restricted to diabetes team initiation only.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Cartridges
- Pre-filled pen
- Vials
Restrictions / Comments:
Important
Biosimilar insulin Lispro (Admelog).
Prescribe by brand and state form.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Cartridges
- Pre-filled pen
- Vials
Restrictions / Comments:
Important
Prescribe by brand and state form.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Cartridges
- Vials
Restrictions / Comments:
Important
Initiation by diabetes team only. Usage is low but available for existing patients
Links :
Indication :
Status :
Formulations :
- Cartridges
- Pre-filled pen
- Vials
Restrictions / Comments:
Important
Prescribe by brand and state form.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Cartridges
- Vials
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Cartridges
- Vials
Restrictions / Comments:
Important
Prescribe by brand and state form.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Important
Sitagliptin is 1st line. Only consider linagliptin in patients with rapidly deteriorating renal function where there is a risk that dose reduction of sitagliptin may not take place.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Important
Reserve combination products for patients in whom the separate components are less appropriate
Links :
Indication :
Status :
Formulations :
- Subcutaneous injection (sc)
Restrictions / Comments:
Important
Preferred
Liraglutide is 1st-line for patients who wish to have a DAILY injection.
Dulaglutide is the preferred WEEKLY injection.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Modified release tablets
- Tablets
Restrictions / Comments:
Important
Preferred
NOTE: 1g oridnary tablets are disproportionately expensive in primary care. 1g modified release tablets are recommended.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Oral solution
- Powder
Restrictions / Comments:
Important
Oral solution should be reserved for patients with enteral feeding tubes or those unable to swallow tablets.
Sachets of powder for oral solution are preferred in patients with swallowing difficulties in primary care.
Formulary Status :
Links :
45. Metformin hydrochloride/pioglitazone
Drug:
Metformin hydrochloride/pioglitazone
(Antidiabetic drugs)
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Important
Not a cost-effective option. Prescribe as separate components.
Formulary Status :
Links :
46. Metformin hydrochloride/sitagliptin
Drug:
Metformin hydrochloride/sitagliptin
(Antidiabetic drugs)
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Important
Reserve combination products for patients in whom the separate components are less appropriate
Links :
47. Metformin hydrochloride/vildagliptin
Drug:
Metformin hydrochloride/vildagliptin
(Antidiabetic drugs)
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Important
Sitagliptin is the preferred DPP4. Reserve combination products for patients in whom separate components are less appropriate. Existing patients would not be expected to change therapy unless appropriate to do so.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Important
Existing patients would not be expected to change therapy unless appropriate to do so.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Subcutaneous injection (sc)
Restrictions / Comments:
Important
Dulaglutide is 1st line.
Semaglutide is the 2nd line option for WEEKLY injection. Max of 13 Ozempic pens per patient per year (1 pen is a 4 week supply).
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Important
Oral semaglutide is not a preferred route due to poor availability and gastrointestinal side effects.
Use may be appropriate in a small cohort of patients where injection isn't suitable.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Preferred
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Cartridges
- Vials
Restrictions / Comments:
Important
Initiation by diabetes team only
Links :
Indication :
Status :
Formulations :
- Vials
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Cartridges
- Vials
Restrictions / Comments:
Important
Prescribe by brand and state form.
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Important
Sotagliflozin is not yet available in the NHS. The NICE TA622 will not be implemented until the product is available. Place in therapy will also be determined at this time.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Subcutaneous injection (sc)
Restrictions / Comments:
Important
Dulaglutide is the preferred weekly injection. Semaglutide is an alternative for weekly injections.
Tirzepatide is 3rd line where dulaglutide / semaglutide are unsuitable or unavailable.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Important
Existing patients would not be expected to change therapy unless appropriate to do so.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Device
Restrictions / Comments:
Important
Note; Neither Continuous Glucose Monitoring (CGM) nor Omnipod 5 is commissioned for this cohort.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Device
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Injection
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Injection
Restrictions / Comments:
Formulary Status :
Links :